Santhera Pharmaceuticals Holding AG Total Liabilities
Santhera Pharmaceuticals Holding AG total liabilities. Based on the latest financial reports, Santhera Pharmaceuticals Holding AG (SANN) has total liabilities worth CHF159.90 Million CHF (≈ $202.16 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SANN asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Santhera Pharmaceuticals Holding AG (2006–2025)
Total liabilities of Santhera Pharmaceuticals Holding AG from 2006 to 2025. This chart illustrates how Santhera Pharmaceuticals Holding AG's total liabilities have evolved over time, based on quarterly financial data. Explore Santhera Pharmaceuticals Holding AG strategic investment ratio to see how much of total assets are deployed in long-term investments.
Santhera Pharmaceuticals Holding AG Competitors by Total Liabilities
The table below lists competitors of Santhera Pharmaceuticals Holding AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sichuan Langsha Holding Ltd
SHG:600137
|
China | CN¥139.62 Million |
|
GSR IV Acquisition Corp. Class A ordinary share
NASDAQ:GSRF
|
USA | $9.24 Million |
|
YG-1 Co. Ltd
KQ:019210
|
Korea | ₩761.54 Billion |
|
Touchstone International Medical Science Co Ltd
SHG:688013
|
China | CN¥76.41 Million |
|
Evolution Global Acquisition Corp Class A Ordinary Shares
NASDAQ:EVOX
|
USA | $9.87 Million |
|
Hainan Yedao Group Co Ltd
SHG:600238
|
China | CN¥742.70 Million |
|
J.G.CHEMICALS LIMITED
NSE:JGCHEM
|
India | Rs282.86 Million |
|
Beijing New Universal Science and Technology Co Ltd
SHE:300472
|
China | CN¥971.07 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Santhera Pharmaceuticals Holding AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Santhera Pharmaceuticals Holding AG's balance sheet.
Liquidity & Leverage Metrics
Santhera Pharmaceuticals Holding AG Total Liabilities Ratios Explained
Santhera Pharmaceuticals Holding AG total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -13.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Santhera Pharmaceuticals Holding AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Santhera Pharmaceuticals Holding AG (2006–2025)
The table below shows the annual total liabilities of Santhera Pharmaceuticals Holding AG from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CHF159.90 Million ≈ $202.16 Million |
+28.14% |
| 2024-12-31 | CHF124.79 Million ≈ $157.77 Million |
+151.16% |
| 2023-12-31 | CHF49.69 Million ≈ $62.82 Million |
-53.74% |
| 2022-12-31 | CHF107.41 Million ≈ $135.80 Million |
+19.63% |
| 2021-12-31 | CHF89.79 Million ≈ $113.52 Million |
-5.53% |
| 2020-12-31 | CHF95.04 Million ≈ $120.16 Million |
+1.32% |
| 2019-12-31 | CHF93.80 Million ≈ $118.59 Million |
+13.75% |
| 2018-12-31 | CHF82.47 Million ≈ $104.26 Million |
+6.37% |
| 2017-12-31 | CHF77.52 Million ≈ $98.01 Million |
+371.53% |
| 2016-12-31 | CHF16.44 Million ≈ $20.79 Million |
+50.77% |
| 2015-12-31 | CHF10.90 Million ≈ $13.79 Million |
+91.08% |
| 2014-12-31 | CHF5.71 Million ≈ $7.22 Million |
+117.00% |
| 2013-12-31 | CHF2.63 Million ≈ $3.33 Million |
-59.88% |
| 2012-12-31 | CHF6.55 Million ≈ $8.29 Million |
-27.57% |
| 2011-12-31 | CHF9.05 Million ≈ $11.44 Million |
-0.97% |
| 2010-12-31 | CHF9.14 Million ≈ $11.55 Million |
-18.32% |
| 2009-12-31 | CHF11.19 Million ≈ $14.15 Million |
+32.05% |
| 2008-12-31 | CHF8.47 Million ≈ $10.71 Million |
-2.17% |
| 2007-12-31 | CHF8.66 Million ≈ $10.95 Million |
-16.29% |
| 2006-12-31 | CHF10.35 Million ≈ $13.08 Million |
-- |
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pi… Read more